Dr Jyoti Bajpai

Dr (Prof) Jyoti Bajpai is the Lead-Medical and Precision Oncology at Apollo Hospitals, Navi Mumbai and Maharashtra, and a Visiting Consultant at Sir HN Reliance Foundation Hospital and Research center, Mumbai. Her immediate past affiliation was the prestigious Tata Memorial Centre, Mumbai as a Professor for 15 years.

Her oncology training involves leading institutes including All India Institute of Medical Sciences, India, Memorial Sloan Kettering, Johns Hopkins, USA, and she is an ESMO leader’s generation program graduate.

She is a proponent of work force equity and was pivotal in pioneering the Indian Immuno-oncology Society of India (founder general secretary), Women in oncology (W4O) –India and SAARC nations (founder chair). Additionally, she is a core member of the global access and impact committee of Society of Immunotherapy of Cancer (SITC), and ESMO -W4O; and faculty for ESMO-Immunotherapy track, and immediate past faculty for Sarcomas. She is invited as a core member and expert for LGBTQ+ cancers for ASCO diversity committee, core member of Europe -Asia Rare cancer mission. She contributed towards the development of international guidelines for ESMO, SITC, ABC, BCY-7 and ESMO-PAGA for breast cancer, sarcoma, gynecology and Immunotherapy. She is a member of the editorial and review board of several international journals and part of several investigator initiated and multi-institutional trials. 

She is an avid researcher with 197 publications to her credit in her core areas (rare cancers like sarcomas and pregnancy associated cancers), Women cancers (breast and gynecology), Immuno-oncology, building low-cost efficacious protocols for low- and middle– income countries and gender equality in high impact Journals. She has represented the country and continent for prestigious international guidelines e.g. ESMO, SITC, ABC and ESMO-PAGA guidelines for sarcoma and Immunotherapy and breast and gynecological cancers, and contributed towards several international position papers in rare cancers.

Her work in rare cancer osteogenic sarcoma, which is predominantly a disease of adolescent and young adult cancers, led to development of low cost, easy to administer, outpatient based “OGS-12” protocol with internationally comparable results, which was adopted in prestigious international (ESMO, ARIA) and national guidelines.

She is pivotal in challenging dogmas in LMIC settings and pioneered randomised trials, including in the enhanced supportive care segment, with development of antiemetic regimen with low dose olanzapine for chemotherapy induced nausea and vomiting, scalp cooling for chemotherapy induced alopecia, and acupuncture for chemotherapy induced peripheral neuropathy. These works are widely recognised and a step towards sustainable care for all, including patients in LMICs.

She has rich experience as a primary investigator of several multinational and national trials, rare and aggressive cancer registries, and genomic studies. She is a board member of editorial and reviewer’s boards of international and national Journals. She also mentors students globally while promoting distant mentorship for women leaders.

Session: AYAs In Low- and Middle-Income Countries

Date: Wednesday 4 December

Time: 8.45 am to 10.15 am